Knowledge at the heart of leadership
Welcome to Liftstream - Life Sciences Executive Search and Leadership Advisory

Wendy Yarno elected Chairwomen of Aratana Therapeutics

Aratana Therapeutics, a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals, today announced that the Board of Directors has elected Wendy Yarno as Chairman of Aratana’s Board of Directors. She will … Continue reading

Posted in Executive Appointments | Tagged , , , , , , , , | Leave a comment

Genmab and Novo Nordisk in bispecific antibody deal

Genmab A/S (OMX: GEN) announced it has entered an agreement to grant Novo Nordisk commercial licenses to use the DuoBody technology platform to create and develop  bispecific antibody candidates for two therapeutic programs.  The bispecific antibodies will target a disease … Continue reading

Posted in M&A Finance and Funding | Tagged , , , , , , , | Leave a comment

$40m for rare focused Rhythm

Rhythm announced today the completion of a $40 million Series A financing for its subsidiary, Rhythm Metabolic, Inc., which is developing setmelanotide (RM-493), a novel peptide MC4 agonist for the treatment of obesity caused by genetic deficiencies in the MC4 … Continue reading

Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases | Tagged , , , , , , , , , , , , , , , | Leave a comment

Editas adds CFO and $120m in Series B round

Editas Medicine, a leading genome editing company, today announced that it has raised $120 million in a highly oversubscribed Series B private financing. The financing assembles a broad syndicate of leading public and private investors who underpin many of the … Continue reading

Posted in Executive Appointments, M&A Finance and Funding | Tagged , , , , , , , , , , , , , , | Leave a comment

Oxford Nanopore Technologies raises £70m

Oxford Nanopore Technologies Ltd, the UK-based technology company that has designed and produced the world’s first DNA sequencer based on nanopore sensing, making it commercially available in 2014, has raised £70 million ($109 million) in new funding through a private … Continue reading

Posted in M&A Finance and Funding | Tagged , , , , , | Leave a comment

Jeremy Levin hauls in $75m Series B for Ovid

Ovid Therapeutics Inc. (Ovid), a privately held biopharmaceutical company focused on developing therapies for rare and orphan diseases of the brain, announced today that it has completed a Series B financing totaling $75 million. Fidelity Management and Research Company led … Continue reading

Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases | Tagged , , , , , , | Leave a comment

Dimension Therapeutics Diversifies Leadership with Management and Board Appointment

Dimension Therapeutics, a leading rare disease company advancing novel, liver-directed treatments for diverse genetic disorders has announced that it has expanded its Board of Directors with the elections of Georges Gemayel, Ph.D., former Executive Vice President of Genzyme Corporation, and Arlene M. … Continue reading

Posted in Executive Appointments, Orphan Drugs and Rare Diseases | Tagged , , , , , , , , , , , , , , , , , , | Leave a comment

Cortendo joins a rare disease crowd in Ireland

  Sweden’s Cortendo AB  has announced its intention to relocate the parent company of the Cortendo group from Sweden to Ireland. The Company is contemplating effecting such redomiciliation through an exchange offer in which Cortendo plc, a newly incorporated Irish … Continue reading

Posted in M&A Finance and Funding | Tagged , , , , , , , , , , | Leave a comment

Shire goes hostile on Baxter spin-out Baxalta

Fresh from announcing that the company will acquire Foresight BioTherapeutics for $300m (here), Shire stepped up its ambitions to acquire the recently spun-out Baxalta, which went public earlier this summer (here). Shire originally approached the Baxalta Board of Directors earlier … Continue reading

Posted in M&A Finance and Funding | Tagged , , , , , , , , , , , , | Leave a comment

BrainStorm recruits new CFO

BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced that it has appointed Yoram Bibring as Chief Financial Officer, effective July 30, 2015. Mr. Bibring will be responsible for all corporate … Continue reading

Posted in Executive Appointments | Tagged , , , , , , | Leave a comment




Contact Us

   Liftstream Ltd.
67 Grosvenor Street
London
W1K 3JN

   Tel: ​+44 (0)20 3178 5864
   info@liftstream.com

Register your CV

Apply for sector specific vacancies or request a confidential discussion



Registered in England No: 5009233
VAT: 843679292

Follow Us





Sitemap